key: cord-1052680-g7ebao0e
authors: Zheng, David X.; Cullison, Christopher R.; Mulligan, Kathleen M.; Scott, Jeffrey F.
title: COVID-19 and the Surveillance, Epidemiology, and End Results Program: Future considerations for skin cancer research
date: 2021-03-31
journal: J Plast Reconstr Aesthet Surg
DOI: 10.1016/j.bjps.2021.03.044
sha: 6cf8622956b8b9fc21b3e1b4409554e2394e0740
doc_id: 1052680
cord_uid: g7ebao0e

nan

The coronavirus disease 2019 (COVID-19) pandemic has drastically impacted the care and management of patients with cutaneous malignancies. 1 Cancer databases are commonly used by clinician-researchers to analyze skin cancer outcomes at the population level and may provide insights into the downstream consequences of COVID-19 on skin cancer patients. 2 Among these is the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program, which collects data on cancer incidence, treatment, and outcomes from population-based cancer registries encompassing approximately 35% of the United States population. 3 Herein, we present considerations regarding the potential effects of COVID-19 on both skin cancer patient outcomes and researchers' ability to track these outcomes through SEER.

Many skin cancer patients likely experienced interruptions to their natural disease trajectory because of COVID-19. Pandemic-related disruptions to standard of care may influence outcomes such as stage at diagnosis, survival, and disease-specific death such that these outcomes become unrepresentative of skin cancers treated prior to the pandemic. 3 For example, fewer urgent skin cancer referrals have been reported during the pandemic, 4 suggesting that patients harboring undiagnosed skin cancer might present with more advanced disease. Delays in time to first definitive treatment for newly diagnosed patients may also result in further progression of disease. 4 These clinical care patterns may portend a population-level shift in the distribution of skin cancer stages recorded within SEER throughout the pandemic era relative to previous years. Cutaneous malignancies also most commonly occur in immunosuppressed and older individuals, which are also the demographics at higher risk of experiencing severe complications due to COVID-19. 1,5 Therefore, skin cancer patients infected by COVID-19 may have seen the natural history of their cancer altered by complications from the virus (e.g. hospitalization), also potentially influencing survival outcomes. Patients whose lives were lost prematurely to COVID-19 will eventually be recorded in SEER. These data will play a vital role in guiding our understanding of the downstream effects of treatment delays and COVID-19related complications on outcomes for skin cancer.

It is yet unclear how SEER will adjust for COVID-19's effect on cancer outcomes, including skin cancer outcomes. However, Hurricanes Katrina and Rita (August and September 2005, respectively) serve as a notable precedent. In the wake of these natural disasters, SEER excluded six months of data (from July to December 2005) for new cancer cases reported by the Louisiana Tumor Registry. 3 Given the much larger scale of the COVID-19 crisis, exclusion of all skin cancer cases diagnosed in 2020 does not seem to be a realistic solution. Furthermore, such an adjustment may detract from SEER's potential role in aiding public health research on cancer outcomes during and due to the pandemic. As we begin to recognize the long-term impacts of COVID-19 on skin cancer patients, the National Cancer Institute must adapt the SEER registry coding structure appropriately. Regardless of the COVID-19-related changes made within SEER, skin cancer researchers should note these adjustments as they occur and account for them in outcome analyses to mitigate any bias they might introduce.

Options for maintaining the research utility and integrity of the SEER Program in the post-pandemic era must be considered. One modification might involve providing COVID-19 as a listed cause of death in SEER. Based on current coding, COVID-19-related deaths would likely be categorized in SEER as "pneumonia and influenza" or "lungs and bronchus," both of which inadequately distinguish death due to COVID-19 from death due to similar causes. 3 Should this change be incorporated, researchers could then decide whether to exclude patients who died prematurely due to COVID-19 from their study design. Additionally, creation of a time to treatment variable in SEER may help differentiate skin cancer patients who experienced COVID-19-related treatment delays from those who did not. 4 Of note, time to treatment data is included in the National Cancer Database, 2 which serves as a reference for its potential incorporation into SEER. Rapid prospective implementation of coding structures in SEER that account for COVID-19's effect on skin cancer would prevent loss of valuable data informing its management and epidemiology. From a public health standpoint, we should recognize the ramifications of the pandemic on the treatment and care of skin cancer patients, as well as act preemptively to accurately characterize its influence on skin cancer behavior and outcomes in future database studies.

Financial disclosure: The authors report no funding sources relevant to this work

Management of primary skin cancer during a pandemic: Multidisciplinary recommendations

Big data in dermatology: Publicly available health care databases for population health research

Major fall in urgent skin cancer referrals during the COVID-19 outbreak

Impact of COVID-19 geographic distribution on advanced age plastic surgeons: A cross-sectional analysis

Ethical approval: Not required